Teva(TEVJF)

Israel - Petach TikvaPharmaceutical11 H-1B visas (FY2023)

Focus: Teva is a global pharmaceutical leader headquartered in Israel with a diversified portfolio spanning small molecules and biologics across neurology, cardiovascular, oncology, infectious diseases, and immunology. The company generates ~$15B in annual revenue with significant exposure to both branded and generic products.

Neurology Cardiovascular Oncology Infectious Diseases

Profile data last refreshed 13h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

Recent layoff filing — 205 affected

11/18/2025 — Salt Lake City, UT · 205 affected · Layoff Amendment

Source: state DOL filings via Big Local News

About Teva

AI assessmentNot Hiring

No open roles listed right now. Follow Teva to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

5/9 — Partial

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

8 imminent

ADASUVE

Hiring

Stable

Revenue

$1.5B

FY2025

Key Products

AUSTEDO

Huntington's disease

$1.1B Part D

Peak12.1yr

Flagship product generating 35% of company revenue with extended patent protection; core to financial stability and justification for high R&D spend.

Help build intelligence for Teva

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

AUSTEDO generates $1.1B in Part D spending and is at peak lifecycle with patent protection until 2038–2041, providing stable revenue and R&D funding for adjacent programs like SD-809 (Huntington's chorea, Phase 3).
High R&D intensity (64%) and diverse pipeline across neurology, sleep disorders, asthma, oncology, and contraception indicate sustained investment in drug development despite near-term patent expirations.
Public company stability with $3.2B cash position as of FY2025 and recent Q1 2026 earnings beat signals operational momentum and investor confidence after turnaround narrative.

Watch Out For

Recent layoff activity (259 employees cut from Salt Lake City operations across June 2025 and November 2025) signals cost restructuring and potential role instability, particularly in manufacturing and specialty functions.
Heavy reliance on AUSTEDO (35% of revenue) combined with LOE approaching for COPAXONE and LYRICA creates medium-term revenue cliff risk; FY2025 revenue declined sharply to $1.5B (likely segment reporting artifact) with $559M net loss despite $953M R&D spend.

Generated by Claude from Teva's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

AUSTEDO XR

Huntington's disease

$91M Part D

Peak14.8yr

Extended-release formulation of lead asset, providing line extension upside and further patent runway into 2041.

COPAXONE

Multiple sclerosis

$369M Part D

LOE Approaching

Second-largest revenue contributor facing imminent loss of exclusivity, representing significant revenue cliff risk requiring replacement from pipeline.

BELBUCA

Chronic pain

$150M Part D

Peak6.3yr

Opioid formulation with patent protection through 2032; stable contributor with controlled growth in pain management segment.

LYRICA

Neuropathic pain, seizures

$72M Part D

LOE Approaching

Structural analog of GABA facing approaching exclusivity; declining revenue reflects competitive generic penetration in CNS/pain category.

AMLODIPINE BESYLATE

Hypertension, angina

$140M Part D

Post-LOE

Established generic antihypertensive with stable baseline revenue; represents mature portfolio segment generating modest but reliable contribution.

METOPROLOL SUCCINATE

Hypertension, heart failure

$80M Part D

Post-LOE

Off-patent beta-blocker in stable decline; generic portfolio pillar with predictable margin structure but limited growth.

ARIPIPRAZOLE

Schizophrenia, Tourette's disorder, bipolar disorder

$72M Part D

Post-LOE

Off-patent atypical antipsychotic with atypical indication mix including Tourette's; stable commodity generic with moderate competition.

Pipeline & Clinical Trials

Digihaler Albuterol Device by TEVA

Asthma in Children

N/A

The Ribavirin Pregnancy Registry

Birth Defects

N/A

Protocol Intervention Group

Huntington Disease

N/A

Clinical Trials (1)

NCT03417583Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease Patients

N/A

extra fine particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler

Asthma

N/A

Clinical Trials (1)

NCT01400217Qvar Versus Clenil, a General Practice Research Database Study

N/A

Systematic detection of vascular risk factors and subsequent evidence-based treatment

Stroke

N/A

ProAir Digihaler

COPD

N/A

Clinical Trials (1)

NCT04821869ProAir Digihaler in COPD Disease Management: A Real World Study

N/A

Copaxone

Multiple Sclerosis

N/A

Clinical Trials (4)

NCT00202982A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose

Phase 2

NCT00203073A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.

Prospective Observational Study in Patients With Metastatic Breast Cancer Treated With Anthracycline

Metastatic Breast Cancer

N/A

Clinical Trials (1)

NCT01555944Prospective Observational Study in Patients With Metastatic Breast Cancer Treated With Anthracyclines

N/A

formoterol

Asthma

N/A

Clinical Trials (2)

NCT05831566Expertise Asthma COPD Program with Digital Support

Phase 3

NCT00643578Dose-response of Inhaled Formoterol Using Methacholine Challenge as a Bioassay

N/A

rasagiline mesylate

Parkinson's Disease

N/A

Naturalistic Adasuve Clinical Trial Study

Agitation

N/A

Clinical Trials (1)

NCT02877108Naturalistic Adasuve Clinical Trial Study

N/A

Initiation of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device

Asthma

N/A

Clinical Trials (1)

NCT01313585Device Mixing in Asthma, a General Practice Research Database Study

N/A

Extra-fine hydrofluoroalkane-beclomethasone dipropionate

Asthma

N/A

Clinical Trials (1)

NCT01141439Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management

N/A

Smoking

Asthma

N/A

Clinical Trials (1)

NCT02833727Airway Inflammation and Disease Burden in Asthmatic Smokers

N/A

Sleep Recording

Parkinson Disease

N/A

Clinical Trials (1)

NCT02907723Feasibility of Continuous Sleep Recording in Patients Undergoing Deep Brain Stimulation for Parkinson's Disease

N/A

NAbs testing

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT00336557Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy

N/A

Group R+AD Rasagiline + Antidepressant

Serotonin Syndrome

N/A

Clinical Trials (1)

NCT00955604Azilect + Antidepressant Chart Review

N/A

tDCS

Relapsing Remitting Multiple Sclerosis

N/A

Clinical Trials (1)

NCT02266121Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis

N/A

Albuterol eMDPI DS

Pulmonary Disease, Chronic Obstructive

N/A

Clinical Trials (1)

NCT05241288Digihaler in Chronic Obstructive Pulmonary Disease (COPD)

N/A

The Mycophenolate Pregnancy Registry

Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases

N/A

Correlation Between PET and Advanced MRI in Multiple Sclerosis

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT02869360Correlation Between PET and Advanced MRI in Multiple Sclerosis

N/A

Qvar Therapy in Smoking Asthmatics

Asthma

N/A

Clinical Trials (1)

NCT01729351Qvar Therapy in Smoking Asthmatics

N/A

A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melano

Parkinson's Disease

N/A

Clinical Trials (1)

NCT00203008A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma

N/A

Marketed antagonists

Asthma

N/A

Clinical Trials (1)

NCT02419872Study in Patients' With Persistent Asthma and Chronic Obstructive Pulmonary Disease

N/A

Rasagiline mesylate

Parkinson's Disease

N/A

Clinical Trials (1)

NCT01032486Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease

N/A

Azilect

Parkinson's Disease

N/A

Clinical Trials (2)

NCT02207387Ambulosono Rasagiline Musical Walking Study

N/A

NCT02384512Azilect® In Wearing-Off (AIWO)

N/A

level of agitation

Psychiatric Issue

N/A

Clinical Trials (1)

NCT02713100Self Reported Level of Agitation of Patients Presenting to an Emergency Department

N/A

Fremanezumab

Migraine

N/A

Clinical Trials (1)

NCT03539393Fremanezumab Managed Access Program for Pediatric Patients

N/A

Glatiramer acetate

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT00819195Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis

N/A

Training on BF Spiromax followed by SYMBICORT Turbohaler

Asthma

N/A

Clinical Trials (1)

NCT02570425Comparing Maintenance of Device Mastery With Turbohaler© vs. Spiromax© in Healthcare Professionals naïve to Both Devices

N/A

Effentora®

Cancer

N/A

Clinical Trials (1)

NCT01400854Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and Tolerability

N/A

Bach's Rescue Remedy Cream

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT00972062Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis

N/A

Modafinil/armodafinil

Narcolepsy

N/A

Clinical Trials (1)

NCT01792583The Nuvigil and Provigil Pregnancy Registry

N/A

Extra-fine hydrofluoroalkane-beclometasone dipropionate

Asthma

N/A

Clinical Trials (1)

NCT01697722Real-world Effectiveness and Cost-effectiveness of HFA-beclometasone Compared With ICS/LABA Combination Therapy

N/A

Adenovirus Vaccine Pregnancy Registry

Adenovirus

N/A

Clinical Trials (1)

NCT01584037Adenovirus Vaccine Pregnancy Registry

N/A

Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT02017808Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months

N/A

Ovaleap®

Pregnancy Rate

N/A

Clinical Trials (1)

NCT02809989A Study to Evaluate the Effect of Ovaleap® on the Pregnancy Rate and Clinical Effects as Well as the User-friendliness of the Ovaleap®-Pen.

N/A

Bradykinesia UPDRS Motor Full Examination

Parkinson's Disease

N/A

Clinical Trials (1)

NCT00932581Bradykinesia Subscale Administered Alone Versus Regular Administration: Psychometric Properties

N/A

Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP)

Neoplasms, Unknown Primary

N/A

Clinical Trials (1)

NCT01202786Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP)

N/A

Mindfulness based stress reduction

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT01419301Mindfulness Based Stress Reduction in Multiple Sclerosis (MS)

N/A

Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effe

HIV Infections

N/A

Budesonide, Formoterol Fumarate Dihydrate

Patient Satisfaction

N/A

Clinical Trials (1)

NCT02384577Study to Evaluate Satisfaction and Usability of DuoResp® SPIROMAX® in Asthma and COPD Treatment

N/A

Immediate postpartum placement of IUD

Contraception

N/A

Clinical Trials (1)

NCT02024672Monitoring With Ultrasound Imaging of Intrauterine Device (IUD) Position Placed Immediately After Giving Birth

N/A

Glatiramer Acetate, IFN-beta 1a

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT00819000Therapy Optimization in Multiple Sclerosis (MS)

N/A

A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT00238654A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy

N/A

Extra-fine hydrofluoroalkane beclometasone dipropionate

Asthma

N/A

Clinical Trials (1)

NCT01877954Qvar vs FP in Pediatrics

N/A

Polysomnogram

Obstructive Sleep Apnea

N/A

Clinical Trials (1)

NCT01340781Screening Tools for Obstructive Sleep Apnea (OSA) in Hospitalized Medical Patients

N/A

Glatiramer acetate

Multiple Sclerosis

N/A

Fremanezumab

Migraine

N/A

BUSPAR® 30 mg Tablet

Healthy

PHASE_1

Clinical Trials (1)

NCT00840398Buspirone Hydrochloride 30mg Tablets, Non-Fasting

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 4092 approved products, 147 clinical trials

Top TAs: Neurology, Cardiovascular, Oncology

H-1B (2023): 11 approvals

SEC Filings: 2 available

Portfolio Health

Pre-Launch737 (18%)

Launch1 (0%)

Growth8 (0%)

Peak51 (1%)

LOE Approaching151 (4%)

Post-LOE3144

Therapeutic Area Focus

Neurology

742 marketed125 pipeline

Cardiovascular

623 marketed1 pipeline

Oncology

245 marketed89 pipeline

Infectious Diseases

263 marketed3 pipeline

Financials (FY2025)

Revenue

$1.5B90%

R&D Spend

$953M(64%)14%

Net Income

-$559M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (2)

2025-11-18

205 employees affected— Salt Lake City, UT

2025-06-20

54 employees affected— Salt Lake City, UT

Source: state DOL filings, aggregated via Big Local News

7 active drug shortages

NCT00937157Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)

N/A

166 marketed87 pipeline

Immunology

217 marketed19 pipeline

Metabolic Diseases

182 marketed1 pipeline

Gastroenterology

118 marketed3 pipeline

259 employees cut from Salt Lake City operations (June 2025: 54; November 2025: 205) indicate ongoing restructuring and manufacturing/supply chain optimization.

Recent and substantial layoff activity in manufacturing/operations signals supply chain consolidation and heightened organizational instability; job security at operating sites should be evaluated carefully.

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Teva(TEVJF)

About Teva

Why Work Here

Key Products

Watch Out For

Products & Portfolio (515)

Key Products by Revenue

Other Products (479)

Pipeline & Clinical Trials

Recent News · Teva(10)

Open Jobs (0)

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (2)